Alnylam Pharmaceuticals Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 4,966,331,000.00 | ROE | 15.89 % |
| Balance Sheet | Total Equity | 789,176,000.00 | ROA | 6.32 % |
| Cashflow | Capital Expenditures | -58,697,000.00 | P/FCF | 64.96 |
| Cashflow | Free Cash Flow | 465,383,000.00 | – | – |
| Cashflow | Operating Cash Flow | 524,080,000.00 | P/CF | 57.69 |
| Income | Earnings per Share (diluted) | 2.33 | Div. Yield | – |
| Income | Net Income | 313,747,000.00 | P/E | 96.34 |
| Income | Shares Outstanding | 134,684,000.00 | P/B | 38.31 |
| Income | Total Revenue | 3,713,940,000.00 | P/S | 8.14 |
Ratios calculated on: 10/14/2026
Company Description
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.alnylam.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more